|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RAB11FIP2 |
Gene summary for RAB11FIP2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RAB11FIP2 | Gene ID | 22841 |
| Gene name | RAB11 family interacting protein 2 | |
| Gene Alias | Rab11-FIP2 | |
| Cytomap | 10q26.11 | |
| Gene Type | protein-coding | GO ID | GO:0001678 | UniProtAcc | Q7L804 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 22841 | RAB11FIP2 | HCC1_Meng | Human | Liver | HCC | 2.98e-19 | -2.40e-02 | 0.0246 |
| 22841 | RAB11FIP2 | HCC2_Meng | Human | Liver | HCC | 2.20e-12 | 8.50e-02 | 0.0107 |
| 22841 | RAB11FIP2 | HCC1 | Human | Liver | HCC | 1.97e-05 | 2.73e+00 | 0.5336 |
| 22841 | RAB11FIP2 | HCC2 | Human | Liver | HCC | 1.30e-07 | 2.85e+00 | 0.5341 |
| 22841 | RAB11FIP2 | S014 | Human | Liver | HCC | 6.48e-21 | 1.05e+00 | 0.2254 |
| 22841 | RAB11FIP2 | S015 | Human | Liver | HCC | 6.44e-14 | 7.69e-01 | 0.2375 |
| 22841 | RAB11FIP2 | S016 | Human | Liver | HCC | 1.80e-27 | 1.06e+00 | 0.2243 |
| 22841 | RAB11FIP2 | S028 | Human | Liver | HCC | 4.54e-09 | 4.59e-01 | 0.2503 |
| 22841 | RAB11FIP2 | male-WTA | Human | Thyroid | PTC | 4.28e-18 | 1.23e-01 | 0.1037 |
| 22841 | RAB11FIP2 | PTC01 | Human | Thyroid | PTC | 1.90e-05 | 1.30e-01 | 0.1899 |
| 22841 | RAB11FIP2 | PTC03 | Human | Thyroid | PTC | 4.05e-04 | 1.07e-01 | 0.1784 |
| 22841 | RAB11FIP2 | PTC04 | Human | Thyroid | PTC | 4.38e-11 | 9.39e-02 | 0.1927 |
| 22841 | RAB11FIP2 | PTC05 | Human | Thyroid | PTC | 3.45e-17 | 5.02e-01 | 0.2065 |
| 22841 | RAB11FIP2 | PTC06 | Human | Thyroid | PTC | 1.20e-20 | 4.17e-01 | 0.2057 |
| 22841 | RAB11FIP2 | PTC07 | Human | Thyroid | PTC | 1.53e-30 | 3.57e-01 | 0.2044 |
| 22841 | RAB11FIP2 | ATC09 | Human | Thyroid | ATC | 1.54e-02 | 6.73e-02 | 0.2871 |
| 22841 | RAB11FIP2 | ATC11 | Human | Thyroid | ATC | 1.80e-07 | 3.09e-01 | 0.3386 |
| 22841 | RAB11FIP2 | ATC12 | Human | Thyroid | ATC | 4.33e-05 | 1.15e-01 | 0.34 |
| 22841 | RAB11FIP2 | ATC13 | Human | Thyroid | ATC | 5.24e-23 | 4.25e-01 | 0.34 |
| 22841 | RAB11FIP2 | ATC1 | Human | Thyroid | ATC | 5.16e-03 | 9.41e-02 | 0.2878 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:190382922 | Liver | HCC | positive regulation of cellular protein localization | 199/7958 | 276/18723 | 1.15e-23 | 2.62e-21 | 199 |
| GO:007265921 | Liver | HCC | protein localization to plasma membrane | 177/7958 | 284/18723 | 1.02e-11 | 4.18e-10 | 177 |
| GO:199077821 | Liver | HCC | protein localization to cell periphery | 200/7958 | 333/18723 | 6.07e-11 | 2.23e-09 | 200 |
| GO:190547511 | Liver | HCC | regulation of protein localization to membrane | 113/7958 | 175/18723 | 2.90e-09 | 7.78e-08 | 113 |
| GO:000716322 | Liver | HCC | establishment or maintenance of cell polarity | 133/7958 | 218/18723 | 2.48e-08 | 5.73e-07 | 133 |
| GO:190437521 | Liver | HCC | regulation of protein localization to cell periphery | 83/7958 | 125/18723 | 5.60e-08 | 1.19e-06 | 83 |
| GO:000974322 | Liver | HCC | response to carbohydrate | 149/7958 | 253/18723 | 9.55e-08 | 1.89e-06 | 149 |
| GO:00022211 | Liver | HCC | pattern recognition receptor signaling pathway | 107/7958 | 172/18723 | 1.37e-07 | 2.58e-06 | 107 |
| GO:190307621 | Liver | HCC | regulation of protein localization to plasma membrane | 69/7958 | 104/18723 | 7.58e-07 | 1.17e-05 | 69 |
| GO:003428422 | Liver | HCC | response to monosaccharide | 131/7958 | 225/18723 | 1.32e-06 | 1.91e-05 | 131 |
| GO:000974622 | Liver | HCC | response to hexose | 126/7958 | 219/18723 | 4.81e-06 | 6.06e-05 | 126 |
| GO:190547711 | Liver | HCC | positive regulation of protein localization to membrane | 68/7958 | 106/18723 | 5.50e-06 | 6.82e-05 | 68 |
| GO:000974912 | Liver | HCC | response to glucose | 121/7958 | 212/18723 | 1.24e-05 | 1.39e-04 | 121 |
| GO:190437712 | Liver | HCC | positive regulation of protein localization to cell periphery | 45/7958 | 69/18723 | 1.16e-04 | 9.80e-04 | 45 |
| GO:003001022 | Liver | HCC | establishment of cell polarity | 82/7958 | 143/18723 | 2.38e-04 | 1.79e-03 | 82 |
| GO:004259322 | Liver | HCC | glucose homeostasis | 137/7958 | 258/18723 | 3.59e-04 | 2.49e-03 | 137 |
| GO:190307812 | Liver | HCC | positive regulation of protein localization to plasma membrane | 40/7958 | 62/18723 | 3.84e-04 | 2.62e-03 | 40 |
| GO:003350022 | Liver | HCC | carbohydrate homeostasis | 137/7958 | 259/18723 | 4.45e-04 | 2.98e-03 | 137 |
| GO:000167822 | Liver | HCC | cellular glucose homeostasis | 95/7958 | 172/18723 | 4.95e-04 | 3.24e-03 | 95 |
| GO:007133112 | Liver | HCC | cellular response to hexose stimulus | 85/7958 | 153/18723 | 7.47e-04 | 4.52e-03 | 85 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0414422 | Liver | HCC | Endocytosis | 178/4020 | 251/8465 | 2.03e-14 | 5.22e-13 | 2.91e-13 | 178 |
| hsa0414432 | Liver | HCC | Endocytosis | 178/4020 | 251/8465 | 2.03e-14 | 5.22e-13 | 2.91e-13 | 178 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RAB11FIP2 | SNV | Missense_Mutation | rs778880042 | c.19G>C | p.Ala7Pro | p.A7P | Q7L804 | protein_coding | deleterious(0.01) | benign(0.445) | TCGA-AC-A5EH-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RAB11FIP2 | SNV | Missense_Mutation | c.646N>A | p.Leu216Ile | p.L216I | Q7L804 | protein_coding | deleterious(0.02) | probably_damaging(0.971) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| RAB11FIP2 | SNV | Missense_Mutation | novel | c.244C>G | p.Leu82Val | p.L82V | Q7L804 | protein_coding | tolerated(0.09) | possibly_damaging(0.895) | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
| RAB11FIP2 | deletion | Frame_Shift_Del | novel | c.1256delC | p.Pro419HisfsTer8 | p.P419Hfs*8 | Q7L804 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| RAB11FIP2 | SNV | Missense_Mutation | rs761769278 | c.386N>A | p.Arg129Gln | p.R129Q | Q7L804 | protein_coding | deleterious(0.05) | benign(0.003) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| RAB11FIP2 | SNV | Missense_Mutation | c.319N>T | p.Asp107Tyr | p.D107Y | Q7L804 | protein_coding | deleterious(0) | possibly_damaging(0.492) | TCGA-EK-A2PG-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
| RAB11FIP2 | SNV | Missense_Mutation | c.1301N>A | p.Arg434Lys | p.R434K | Q7L804 | protein_coding | tolerated(0.95) | possibly_damaging(0.745) | TCGA-LP-A5U2-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | |
| RAB11FIP2 | SNV | Missense_Mutation | c.1180N>A | p.Glu394Lys | p.E394K | Q7L804 | protein_coding | tolerated(0.79) | benign(0.113) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| RAB11FIP2 | SNV | Missense_Mutation | novel | c.874N>A | p.Glu292Lys | p.E292K | Q7L804 | protein_coding | tolerated(0.13) | benign(0.003) | TCGA-VS-A9U6-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| RAB11FIP2 | SNV | Missense_Mutation | c.58N>T | p.Leu20Phe | p.L20F | Q7L804 | protein_coding | deleterious(0.01) | possibly_damaging(0.874) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |